March 12, 2020 06:50 AM EDTUpdated 08:16 AM
R&D

Dis­ap­point­ing PhI­II re­sults dash As­traZeneca's hopes of re­viv­ing a tar­nished can­cer drug through Lyn­parza com­bo

Amber Tong

Bare­ly a year af­ter a team at Yale tried to make sense of some un­ex­pect­ed Phase II re­sults around an ovar­i­an can­cer drug that As­traZeneca …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

A service from the Financial Times